Northwestern University

Other

The University of North Carolina at Chapel Hill

Vesseltek Biomedical LLC

Melina R Kibbe

Guillermo A Ameer

Samuel I Stupp

Haichao Zhao

Jian Yang

Mark R Karver

Vinit N Varu

Erica B Peters

Tyson J Moyer

Neel Anand Mansukhani

Miranda So

Edward Moreira Bahnson

Mazen Albaghdadi

Antonio Webb

Nick D Tsihlis

Provided herein are peptide amphiphiles (PAs). In some embodiments, provided herein are targeting PAs comprising a PA backbone and a targeting moiety. In some embodiments, provided herein are therapeutic PAs comprising a PA backbone and a therapeutic agent. In some embodiments, the peptide amphiphiles are co-assembled into nanofibers. In some embodiments, the nanofibers may be used for the treatment of atherosclerosis or related disease.

Drug delivery vehicles for atherosclerosis nanomedicine

Provided herein are tissue factor (TF)-targeted nanofibers and methods of treating hemorrhage in a subject therewith. In particular, peptide amphiphiles (PAs) are provided that comprise a TF-targeting peptide sequence and self-assemble under aqueous conditions into PA nanofibers displaying the TF-targeting sequence on the exterior of the nanofiber.

Tissue factor (TF)&#x2014;targeted nanotherapy

Disclosed are balloon catheters for forming liquid cast biodegradable arterial stents, typically, the balloon catheters include multiple balloons and multiple ports and include an element for promoting or initiating curing of a polymer solution via polymerization or cross-linking.

Triple balloon occlusion and infusion catheter for forming a stent in situ

Disclosed are liquid cast biodegradable arterial stents and methods for preparing liquid cast biodegradable arterial stents. The typically includes a biodegradable polymer and may include an agent for treating neointimal hyperplasia.

Liquid cast biodegradable arterial stent

Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator.

Pharmaceutical compositions and methods for digesting atherosclerotic plaques

Provided herein are compositions and methods for targeted drug delivery to prevent restenosis in the cardiovascular system. In particular, provided herein are nanoscale delivery vehicles for drugs that prevent proliferation and neointimal hyperplasia.

Targeted therapy for the prevention of restenosis in the cardiovascular system

Controlled release vascular implants, such as vascular grafts, stents, wraps, and gels comprising a biocompatible polymer and all trans retinoic acid (ATRA), or its derivatives, can be used to treat, prevent, or inhibit thrombosis and/or neointimal hyperplasia which may otherwise be induced by prosthetic implantation. In particular, the implants herein can inhibit smooth muscle cell proliferation, neointimal hyperplasia, and upregulate antithrombotic genes and nitric oxide production in the vasculature. Further, the implants are capable of delivering controlled and predictable localized concentrations of ATRA.

Controlled and localized release of retinoids to improve neointimal hyperplasia

Disclosed herein is a biodegradable nitric oxide-generating polymer comprising a nitric oxide-releasing NO(NONOate) functional group. The polymer can be applied to various medical devices for the treatment of various diseases such as thrombosis and restenosis.

Biodegradable nitric oxide generating polymers and related biomedical devices

The present invention is directed to a novel poly(diol citrates)-based coating for implantable devices. More specifically, the specification describes methods and compositions for making and using implantable devices coated with citric acid copolymers or citric acid copolymers impregnated with therapeutic compositions and/or cells.

Growing community of inventors

Chicago, IL, United States of America

Melina R Kibbe